MEM 1414

MEM 1414 is a novel, oral small molecule inhibitor of phosphodiesterase-4 (PDE4), developed for its potential to treat diseases involving inflammation and cognitive dysfunction. By selectively inhibiting PDE4, MEM 1414 increases levels of cyclic adenosine monophosphate (cAMP) in the brain and immune cells. This mechanism is thought to enhance memory formation by acting in brain regions critical for new memory storage and may also provide anti-inflammatory effects relevant to respiratory diseases such as asthma. The drug has demonstrated efficacy in preclinical models of inflammation and has shown a favorable safety profile in multiple human clinical studies, with typical PDE4 inhibitor side effects such as mild nausea and vomiting[1][2][3][6].